Global operations and clinical drug development professional who has grounded technical expertise in financial results. Managed external manufacturing at venture-backed biotech spin-outs of Stanford and Johns Hopkins ($40MM Series A: Earli, $69MM Series B: Ashvattha, NYSE: GRAY). MBA in Finance. Published, patent-pending chemical and biomolecular engineer. Currently leading Chemistry, Manufacturing, and Controls (CMC) for clinical-stage biotech leveraging biology to produce canceractivated synthetic biomarkers designed to detect the exact location of malignancies, so they can be treated early via precision surgery, targeted radiation, or targeted therapeutics.